2012.06.25 Quiz: Novel agents for anti-platelet therapy

Which of the following is false regarding some novel anti-platelet therapy?
A. Among the platelet glycoprotein (GP) IIb/IIIa receptor antagoinists (abciximab, eptifibatide, tirofiban), abciximab has the disadvantage of potential immunogenicity.
B. Oral GP IIb/IIIa antagonists demonstrate even better benefit than intravenous formulations in reducing mortality in acute coronary syndrome.
C. Among the P2Y(12) receptor antagonists (clopidogrel, prasugrel, cangrelor, ticagrelor), clopidogrel has the disadvantages of high inter-individual variability in pharmacological response, delayed onset and offset of action, as well as requiring to be metabolized to its active metabolite form.
D. Cilostazol, a kind of selective inhibitor of cAMP-phosphodiesterase, is an anti-platelet agent for treatment of peripheral ischemia. It can be used with aspirin.
E. The protease-activated receptor (PAR) antagonists (vorapaxar, atopaxar) under research are available in oral forms.